What type of study is this?

This is a Cohort Study study (also classified as: Experimental Study).

October 9, 2025Circulation Research

Abstract Thu022: Mitochondrial Dysfunction and Metabolic Therapies for Heart Failure Derived From the Pediatric Heart

Q: What are the key findings of this study?

Treatment with pediatric cardiac progenitor cell secretome and specifically Enolase-1 (ENO1) improved tissue contractility, mitochondrial function, and respiration in hypoxic cardiomyocytes (p<0.01).

Q: What is the clinical evidence from this study?

Study design: Other. Population: Heart failure / Ischemic cardiac injury (n=100). Intervention: Pediatric cardiac progenitor cell secretome and Enolase-1 (ENO1) vs. Untreated / Hypoxia control. Primary outcome: Tissue contractility, mitochondrial mass and polarization, basal and maximal respiration, and ATP/ADP ratio (p=<0.01).

View Full Paper

Ask AI

Bookmark

Key result

Cardiac progenitor cell secretome and ENO1 improve contractility and mitochondrial function in hypoxic cardiomyocytes.

P<0.01
n=100

Population

100 cardiac tissue samples from children undergoing open heart surgery, matured stem cell-derived…

Design

Preclinical

Authors

FLFatemeh Mirshafiei LangariHospital for Sick Children TLTim LeeHospital for Sick Children KHKaley HogarthUniversity of Toronto

Discussion

Member takes

Implication

Metabolic regulators, specifically enolase-1 (ENO1), derived from the pediatric heart secretome can improve contractile function and mitochondrial respiration in injured cardiomyocytes, suggesting a potential novel metabolic therapy for heart failure.

Key Points

Secretome treatment significantly improved cardiac contractility and mitochondrial function in cardiomyocytes.
Mass spectrometry identified over 400 proteins with ENO1 as a key metabolic regulator linked to improved heart function.
Injecting secretome into rats post-LAD ligation enhanced cardiac performance, indicating potential therapeutic pathways.
Transfer of pediatric heart regulatory mechanisms may offer new approaches for adult heart failure treatments.

Structured PICO

Population

100 cardiac tissue samples from children undergoing open heart surgery used to isolate cardiac progenitor cells for secretome analysis and testing in hypoxic iPSC-CMs and rat LAD ligation models.

Intervention

Treatment with pediatric cardiac progenitor cell secretome, enolase-1 (ENO1) over-expression, or recombinant ENO1 encapsulated in lipid nanoparticles (LNP).

Outcome

Tissue contractility, mitochondrial mass and polarization, basal and maximal respiration, and ATP/ADP ratio.surrogate

Main Result

p-value: p=<0.01

Cite This Study

Langari et al. (2025) studied Heart failure / Ischemic cardiac injury (n=100). Pediatric cardiac progenitor cell secretome and Enolase-1 (ENO1) vs. Untreated / Hypoxia control was evaluated on Tissue contractility, mitochondrial mass and polarization, basal and maximal respiration, and ATP/ADP ratio (p=<0.01). Treatment with pediatric cardiac progenitor cell secretome and specifically Enolase-1 (ENO1) improved tissue contractility, mitochondrial function, and respiration in hypoxic cardiomyocytes (p<0.01).

synapsesocial.com/papers/68e77f09d1c187e1c108fc12 https://doi.org/10.1161/res.137.suppl_1.thu022

View Full Paper

Ask AI

Bookmark

Abstract Thu022: Mitochondrial Dysfunction and Metabolic Therapies for Heart Failure Derived From the Pediatric Heart

Discussion

Member takes

Implication

Key Points

Structured PICO

Main Result

Cite This Study

Abstract Thu022: Mitochondrial Dysfunction and Metabolic Therapies for Heart Failure Derived From the Pediatric Heart

Discussion

Member takes

Implication

Key Points

Structured PICO

Main Result

Cite This Study

Also Consider

Also Consider